Radiopharmaceuticals hit safety snags in clinical trials
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Radiopharmaceuticals have been pitched as a way to deliver radiation directly to tumors instead of "crop-dusting" healthy tissue the way conventional beam radiation does, a targeted approach that has generated major drug-industry interest and a new drug-development field.
- As more radiopharmaceuticals move into clinical trials, developers are finding the approach is "not so clear-cut," with the article flagging unintended damage during the drugs' journey to tumors.
- The isotopes at the core of radiopharmaceuticals are described as just as virulent as the beam radiation patients have tolerated for decades — powerful enough that some inadvertently zap patients' kidneys, liver, or bone marrow while en route to their biological targets.
- The safety problem is inherent to the delivery mechanism: the article frames the damage as occurring while isotopes are "hurtling to biological bull's-eyes," meaning the toxicity happens in transit, not at the destination.
- STAT+ is publishing the analysis behind a paywall, positioning the piece as part of its subscriber-only biotech coverage.
Why it matters: Radiopharmaceuticals had been sold to the drug industry on a clean targeting story, but organ-level toxicity in transit complicates both trial design and the commercial pitch. Developers now face a harder regulatory and clinical bar even as investment pours into the field.
Ask SkimNews
